Expression of S100A11 can be up‐ or down‐regulated in colorectal carcinoma, pancreatic ductal adenocarcinoma, and hepatocellular carcinoma, or bladder cancer, respectively [26, 27, 28, 29]. Here, S100A11 is linked to urinary bladder carcinoma.